MOLECULAR PATHOGENESIS OF GENETIC AND INHERITED DISEASES

The Accumulation of Heparan Sulfate S-Domains in Kidney Transthyretin Deposits Accelerates Fibril Formation and Promotes Cytotoxicity

Hirokazu Kameyama,^{*} Kenji Uchimura,^{†‡} Taro Yamashita,[§] Kaori Kuwabara,^{*} Mineyuki Mizuguchi,[¶] Shang-Cheng Hung,^{||} Keiichiro Okuhira,^{*} Tomohiro Masuda,^{**} Tomoki Kosugi,^{**} Takashi Ohgita,^{††} Hiroyuki Saito,^{††} Yukio Ando,[§] and Kazuchika Nishitsuji^{†‡§§}

From the Departments of Molecular Physical Pharmaceutics* and Pathology and Laboratory Medicine,^{§§} Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan; the Departments of Biochemistry[†] and Nephrology,^{**} Nagoya University Graduate School of Medicine, Nagoya, Japan; the Unité de Glycobiologie Structurale et Fonctionnelle,[‡] UMR 8576 CNRS, Université de Lille 1, Villeneuve d'Ascq, France; the Department of Neurology,[§] Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; the Faculty of Pharmaceutical Sciences,[¶] University of Toyama, Toyama, Japan; the Genomics Research Center,^{||} Academia Sinica, Taipei, Taiwan; the Department of Biophysical Chemistry,^{††} Kyoto Pharmaceutical University, Kyoto, Japan; and the Department of Biochemistry,^{†‡} Wakayama Medical University, Wakayama, Japan

Accepted for publication
September 26, 2018.

Address correspondence to
Kazuchika Nishitsuji, Ph.D.,
Department of Biochemistry,
Wakayama Medical University,
811-1 Kimiidera, Wakayama
641-8509, Japan. E-mail:
nishit@wakayama-med.ac.jp.

The highly sulfated domains of heparan sulfate (HS), alias HS S-domains, are made up of repeated trisulfated disaccharide units [iduronic acid (2S)-glucosamine (NS, 6S)] and are selectively remodeled by extracellular endoglucosaminase 6-sulfatases (Sulfs). Although HS S-domains are critical for signal transduction of several growth factors, their roles in amyloidoses are not yet fully understood. Herein, we found HS S-domains in the kidney of a patient with transthyretin amyloidosis. In *in vitro* assays with cells stably expressing human Sulfs, heparin, a structural analog of HS S-domains, promoted aggregation of transthyretin in an HS S-domain-dependent manner. Interactions of cells with transthyretin fibrils and cytotoxicity of these fibrils also depended on HS S-domains at the cell surface. Furthermore, glypican-5, encoded by the susceptibility gene for nephrotic syndrome *GPC5*, was found to be accumulated in the transthyretin amyloidosis kidney. Our study, thus, provides a novel insight into the pathologic roles of HS S-domains in amyloidoses, and we propose that enzymatic remodeling of HS chains by Sulfs may offer an effective approach to inhibiting formation and cytotoxicity of amyloid fibrils. (*Am J Pathol* 2019, 189: 308–319; <https://doi.org/10.1016/j.ajpath.2018.09.015>)

Highly sulfated domains of heparan sulfate (HS), alias HS S-domains, consist of consecutive clusters of a trisulfated disaccharide unit [iduronic acid (2S)-glucosamine (NS, 6S)].¹ These HS S-domains are a major determinant of specific interactions between HS and its protein ligands, including growth factors, chemokines, and morphogens, and thus they regulate HS functions in diverse biological processes.^{2,3} In addition to being involved in biological processes, HS is associated with various amyloid deposits, including those in transthyretin amyloidosis (ATTR amyloidosis),⁴ Alzheimer disease (AD),^{5–7} light-chain amyloidosis,⁸ and amyloid A (AA) amyloidosis,⁹ which suggests that HS may affect amyloid deposition and amyloidosis pathology. Indeed, HS and heparin, whose

major components are HS S-domains, reportedly promoted fibrillogenesis of various amyloidogenic proteins, such as transthyretin (TTR) in ATTR amyloidosis,^{4,10} amyloid β (A β) in AD,^{11–13} cellular prion, Ig light chain in light-chain amyloidosis,¹⁴ and serum AA in AA amyloidosis.^{15–17} Also, HS at the cell surface mediated interactions of cells with and cytotoxicity of amyloid fibrils or protein aggregates, including those of τ protein and α -synuclein,¹⁸ A β ,¹⁹

Supported in part by the Japan Society for the Promotion of Science grants-in-aid for young scientists B-15K19488 (K.N.) and B-17K16123 (K.N.) and the MEXT/JSPS grants-in-aid JP15K08265 (K.U.) and JP16KK0202 (K.U.).

Disclosures: None declared.

and mutant apolipoprotein A-I (apoA-I).²⁰ We and others previously reported that HS S-domains accumulated with tissue amyloid in brains of patients with AD and brains of mouse AD models.^{21,22} These lines of evidence suggest that HS S-domains may be key elements in amyloidosis,²³ a suggestion that is also supported by our previous study showing that HS S-domains mediated interactions of cells with fibrils of the G26R mutant apoA-I and cytotoxicity of these fibrils.²⁰ However, involvement of HS S-domains in other amyloidosis, such as ATTR amyloidosis, which is the most common form of hereditary amyloidosis, has not been addressed.²⁴

Amyloidosis are caused by abnormal depositions of amyloid fibrils. Although the sequences of amyloidogenic proteins vary, amyloid fibrils share a common structure—the cross- β structure.²⁵ Currently, >30 amyloidogenic proteins have been identified in humans.²⁶ TTR in plasma is present as a homotetramer composed of four 14-kDa monomers.²⁷ TTR is predominantly synthesized by the liver and the choroid plexus and transports retinol and thyroxine.²⁸ In addition to having physiological functions, TTR is an amyloidogenic component of amyloid fibrils in several types of amyloidosis, including familial ATTR amyloidosis²⁹ and senile systemic amyloidosis.³⁰ Symptoms of ATTR amyloidosis, which depend on the site of deposition, include peripheral neuropathy, gastrointestinal tract impairment, cardiomyopathy, nephropathy, and ocular manifestations.³¹ Autosomal dominant ATTR amyloidosis caused by variant forms of TTR is the most common form of hereditary amyloidosis. Several endemic foci have been found in Japan, Sweden, and Portugal.³¹ More than 100 amyloidogenic mutations in TTR have been reported,²⁷ although wild-type (WT) TTR also forms amyloid fibrils, which suggests that the mutations are not the sole determinant of amyloid formation.³² Indeed, TTR fibrillization is reportedly initiated by dissociation of tetramers into monomers that can misfold and aggregate into fibrils.³³ In addition, amyloid fibrils do not deposit alone but rather deposit together with nonamyloid protein components³⁴ and nonprotein components.³⁵ These data indicate the existence of a cofactor for formation and deposition of aggregates formed by WT TTR and variant TTRs. ATTR amyloidosis is characterized by deposition of TTR fibrils in various tissues, including the kidney, which is the most frequent site of deposition.³⁶ TTR deposition in the kidney leads to renal injury associated with various clinical manifestations, ranging from proteinuria to end-stage kidney failure.³⁷ As an intriguing finding, HS is the major component of glomerular basement membranes.³⁸

Herein, to identify potential cofactors for TTR deposition in tissues, we studied the involvement HS S-domains in ATTR amyloidosis. HS S-domains were detected in tissues obtained from patients with ATTR amyloidosis by using the RB4CD12 antibody, which specifically recognizes HS S-domains.³⁹ Previously, Chinese hamster ovary (CHO) cells that stably expressed the extracellular endoglucosamine 6-sulfatase human sulfatase 2 (HSulf-2) were established.⁴⁰ Sulf-2 enzymatically remodels extracellular HS by removing C-6 sulfate groups in HS S-domains and thereby

regulates interactions between the HS S-domains and their protein ligands.⁴¹ By using CHO cells that stably expressed the extracellular endoglucosamine 6-sulfatase HSulf-2, it was shown that formation of fibrils and interactions of cells with fibrils generated by various TTR fragments depended on HS S-domains. Moreover, glypican-5 (GPC5) was detected in glomeruli obtained from patients with ATTR amyloidosis. The *GPC5* gene is a recently identified new susceptibility gene for acquired nephrotic syndrome that may confer susceptibility to that syndrome by hyperactivating fibroblast growth factor 2 (FGF2) signaling.⁴² Our results support the importance of HS S-domains and their enzymatic remodeling by Sulf-2 in the pathogenesis of ATTR amyloidosis and development of therapeutic strategies,⁴³ and they point to GPC5 as a new therapeutic target to reduce renal injury in ATTR amyloidosis.

Materials and Methods

Materials

After receiving approval from the Kumamoto University Research Ethical Committee, informed consent was obtained from all study subjects. Table 1 provides details about study subjects and postmortem tissues. Formalin-fixed, paraffin-embedded sections of normal kidney were obtained from BioChain Institute Inc. (Newark, CA), according to ethical standards and procedures approved by the institutional review board. WT TTR 81 to 127 fragments were expressed by *Escherichia coli* and purified. WT TTR, V30M mutant TTR 12 to 35 fragments, and the C-terminal fragment with amino acid residues 105 to 123 were purchased from Eurofins Genomics (Tokyo, Japan). CHO cells that were stably transfected with HSulf-2—encoding cDNA were established as previously described.⁴⁰ A conditionally immortalized human podocyte cell line was established by Saleem et al.⁴⁴ Mouse mesangial cells (SV40 MES 13, number CRL-1927) were purchased from ATCC (Manassas, VA). Porcine intestinal mucosa heparin was coupled to bovine serum albumin (BSA) at its reducing end on the basis of the procedure described by Najjam et al.⁴⁵ The

Table 1 Basic Characteristics of Human Subjects and Postmortem Tissues

Characteristic	Control (n = 2)	ATTR patients (n = 8)
Female/male ratio	2:0	5:3
Age, years	78	44 ± 8.6
Liver transplantation	0	3
Mutation	NA	V30M
Amyloid deposition in the glomeruli	0	5
Accumulation of HS S-domains in amyloid deposits	0	4

Data are expressed as mean or means ± SD, unless indicated otherwise. NA, not applicable.

conjugates were referred to as heparin-BSA. Thioflavin T (ThT) was purchased from Sigma (St. Louis, MO). An anti- β -actin antibody was purchased from Sigma, and a rabbit monoclonal anti-GPC5 antibody was purchased from Abcam (Cambridge, MA). RB4CD12 anti-S-domain antibody²² was kindly provided by Dr. Toin H. van Kuppevelt (Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands). Mouse IgG and IgM isotype controls were obtained from Abcam, and a rabbit IgG isotype control was from Thermo Fisher Scientific (Waltham, MA).

Monitoring Fibril Formation

Fibril formation was monitored by means of ThT,⁴⁶ as previously described,⁴⁷ except that we used Black 96-Well Immuno Plates (Thermo Fisher Scientific) that were coated with BSA (control) or heparin-BSA conjugates. To eliminate S-domains from heparin, each well of the heparin-BSA-coated plate was incubated with the culture medium of CHO cells that stably expressed HSulf-2.⁴⁸ To monitor formation of fibrils by TTR fragments, TTR fragments (30 μ mol/L) in phosphate-buffered saline (PBS; pH 7.4) were incubated in the presence of 10 μ mol/L ThT at 37°C with agitation on an orbital rotator. Fluorescence of ThT was recorded from 460 to 600 nm with an excitation wavelength of 445 nm. The area under the curve was determined by using Prism 7 software (GraphPad Software, La Jolla, CA).

Cell Culture

WT CHO cells and their variants were cultured in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F-12 Nutrient Mixture (Sigma) supplemented with 10% heat-inactivated fetal bovine serum (Lonza Group Ltd, Basel, Switzerland), 100 U/mL penicillin, and 100 μ g/mL streptomycin (Sigma) at 37°C in 95% air and 5% CO₂. Immortalized human podocytes were maintained in RPMI 1640 medium (Thermo Fisher Scientific) containing 10% fetal bovine serum, 1% Insulin-Transferrin-Selenium-A Supplement (Thermo Fisher Scientific), 100 U/mL penicillin, and 100 μ g/mL streptomycin. Cells were grown at 33°C in 95% air and 5% CO₂ and were then differentiated at 37°C for 7 days.⁴⁴ SV40 MES 13 mouse mesangial cells were cultured in a 3:1 mixture of Dulbecco's modified Eagle's medium and Ham's F-12 Nutrient Mixture containing 14 mmol/L HEPES (Sigma), 5% fetal bovine serum, 100 U/mL penicillin, and 100 μ g/mL streptomycin at 37°C in an atmosphere containing 5% CO₂.

Analysis of HS S-Domains by Enzyme-Linked Immunosorbent Assay

Heparin was immobilized by adding 100 ng/mL heparin-BSA conjugates in PBS to wells (100 μ L/well) of Black 96-Well Immuno Plates. The plates were kept at 4°C overnight.

The wells were washed three times with PBS containing 0.1% Tween-20 and were then blocked with 3% BSA (Sigma) in PBS at room temperature for 2 hours, after which the wells were washed with PBS containing 0.1% Tween-20 and incubated with the primary antibody (RB4CD12, 1:750 in 0.1% BSA/PBS, 100 μ L/well) at room temperature for 1 hour. After being washed, the wells were incubated with 100 μ L/well of the secondary antibody, rabbit anti-vesicular stomatitis virus antibody conjugated with Cy5 (Sigma; 1 μ g/mL in 0.1% BSA in PBS), at room temperature for 45 minutes. The fluorescence intensity of each well was analyzed by using an Infinite M200 microplate reader (Tecan Japan Co, Ltd, Kanagawa, Japan).

Preparation of TTR Fibrils

WT TTR, V30M mutant TTR 12 to 35 fragments, the C-terminal fragment with amino acid residues 105 to 123, and WT TTR 81 to 127 fragments were solubilized in PBS to give a final concentration of 30 μ mol/L, and the solutions were incubated in a microcentrifugation tube in a rotating mixer for 7 days at 37°C. Fibril formation was confirmed by using atomic force microscopy (AFM).

AFM Analysis

For AFM analysis, 10 μ L of each fibril solution (30 μ mol/L) in 10 mmol/L PBS was diluted with 45 μ L of distilled water and spotted on freshly cleaved mica (Nilaco Corp., Tokyo, Japan). After the mica was washed with 20 μ L of distilled water, sample images were obtained under ambient conditions at room temperature via NanoScope IIIa Tapping Mode AFM (Veeco Instrument, Plainview, NY) and a single-crystal microcantilever OMCLAC160TS-R3 (Olympus, Tokyo, Japan) at a scan rate of 0.5 Hz in tapping mode.

Analysis of Interactions of Cells with TTR Fibrils

HS S-domain expression and its removal were successfully induced by plating CHO cells and their HSulf-2-expressing variants on coverslips coated with poly-L-lysine to prevent cells from detaching.^{20,40} Cells were plated onto the coated coverslips and cultured for 12 hours, after which they were incubated with CF488A dye-labeled TTR fibrils (1 μ mol/L) at 37°C for 12 hours. TTR fibrils were labeled by using the CF488A Protein Labeling Kit (Biotium, Fremont, CA). Briefly, 100 μ L of 1 mol/L sodium bicarbonate (pH 8.3) was added to 1000 μ L of 30 μ mol/L TTR fibrils in PBS solution. The CF488A dye was dissolved in 25 μ L of dimethyl sulfoxide, and the dye solution was added to the TTR fibril solution. After labeled TTR fibrils were incubated at room temperature in the dark for 1 hour, the fibrils were purified by using ultrafiltration vials with a 3-kDa cutoff (Millipore, Billerica, MA). The cells were fixed with 4% paraformaldehyde for 20 minutes at room temperature. The cells were washed three times with PBS and were mounted with

Vectashield Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA). The specimens were examined with an LSM710 confocal microscope. For quantification of TTR fibril-positive cells, 5 to 10 fields were randomly selected and the percentages of TTR fibril-positive cells was calculated from the total number of cells and number of amyloid-positive cells. The mean ratios of amyloid-positive cells/total cells were obtained.

Cytotoxicity Assay

Cytotoxicity was determined by measuring mitochondrial membrane potential with the mitochondrial membrane potential-sensitive fluorophore tetramethylrhodamine, ethyl ester (MitoPT assay kit; ImmunoChemistry Technologies, Bloomington, MN). Briefly, CHO cells and their variants were plated on poly-L-lysine-coated coverslips, cultured for 12 hours, and treated with TTR fibrils (1 $\mu\text{mol/L}$) at 37°C for 12 hours. After the cells were washed with PBS twice, they were spiked with 10 nmol/L tetramethylrhodamine, ethyl ester, at 37°C for 20 minutes in the dark. Tetramethylrhodamine, ethyl ester, fluorescence was detected by using an LSM710 confocal microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany) with an excitation wavelength of 555 nm. Mean fluorescence intensities were determined using ImageJ software version 1.50i (NIH, Bethesda, MD; <http://imagej.nih.gov/ij>).

Immunohistochemistry

Paraffin-embedded blocks of human tissue were cut into sections (3 μm thick) and stained with alkaline Congo red after deparaffinization and rehydration. Stained specimens were examined under polarized light.⁴⁹ After deparaffinization and rehydration of the sections, antigens were heat retrieved by boiling the sections in a pressure cooker in citrate buffer (10 mmol/L sodium citrate and 0.05% Tween 20, pH 6.0) for 20 minutes, after which sections were blocked in Animal-Free Blocker (Vector Laboratories) for 1 hour at room temperature. Sections were then incubated overnight at 4°C with primary antibodies: an anti-TTR antibody, 1:200 (Dako, Glostrup, Denmark); an anti-FGF2 antibody, 1:200 (Novus Biologicals, Littleton, CO); an anti-GPC5 antibody, 1:200 (Bioss Antibodies, Woburn, MA); the RB4CD12 antibody; the 10E4 anti-HS antibody, 1:50 (United States Biological, Salem, MA); or isotype controls in Animal-Free Blocker. After the samples were washed in PBS, primary antibodies were detected with the secondary antibody Alexa 488-conjugated polyclonal goat anti-rabbit IgG, Alexa 568-conjugated polyclonal goat anti-rabbit IgG, Alexa 568-conjugated polyclonal goat anti-mouse IgG, Alexa 488-conjugated polyclonal goat anti-mouse IgM (5 $\mu\text{g/mL}$; Thermo Fisher Scientific), or Cy3-conjugated monoclonal anti-vesicular stomatitis virus G glycoprotein (4 $\mu\text{g/mL}$; Sigma). Sections were mounted with Vectashield mounting medium and examined with an LSM710 confocal microscope.

Analysis of GPC5 Expression by Means of Western Blot Analysis

MES 13 cells or differentiated human podocytes were treated with fibrils of WT TTR 81 to 127 fragments (1 $\mu\text{mol/L}$) at 37°C for 12 hours. After incubation, cells were washed with PBS three times and were lysed by sonication in RIPA buffer [1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 150 mmol/L NaCl, 50 mmol/L Tris-HCl (pH 8.0), and 1 mmol/L EDTA] containing a protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). Cell lysates were subjected to SDS-PAGE with 4% to 20% gradient gels (Wako Pure Chemicals, Osaka, Japan) and were transferred to polyvinylidene difluoride membranes (Millipore). GPC5 was probed with an anti-GPC5 antibody (Abcam), followed by the secondary antibody (a horseradish peroxidase-labeled anti-rabbit antibody; Cell Signaling Technology, Beverly, MA) and the chemiluminescent substrate ImmunoStar LD (Wako Pure Chemicals). Signals were detected by using a Fujifilm LAS-3000 Imager (Fujifilm, Tokyo, Japan). The protein contents were normalized to the expression level of β -actin protein. To determine protein band densities, image files were analyzed with ImageJ software version 1.50i.

Immunoprecipitation

Cells were incubated with TTR fibrils (1 $\mu\text{mol/L}$) at 37°C for 12 hours, and cell lysates were prepared as described above. GPC5 in cell lysates was immunoprecipitated by using an anti-GPC5 antibody (Abcam) that was conjugated with Dynabeads Protein G (Thermo Fisher Scientific). The precipitates obtained were washed three times with PBS and heat treated at 70°C for 10 minutes in SDS-PAGE sample buffer. HS S-domains in the supernatants were detected by means of SDS-PAGE with 4% to 20% gradient gels, followed by immunoblotting with the RB4CD12 antibody and a horseradish peroxidase-conjugated mouse anti-vesicular stomatitis virus G glycoprotein antibody (Sigma). The signals were visualized and analyzed as described in the above section.

Statistical Analysis

Data were analyzed by means of the unpaired *t*-test. Results were considered significant when $P < 0.05$.

Results

HS S-Domains and TTR Colocalized in the Kidney of an ATTR Amyloidosis Patient

Under polarized light, Congo red staining of sections of the kidney from a patient with ATTR amyloidosis demonstrated apple-green birefringence, which indicated deposition of amyloid fibrils in this specimen (Figure 1A). Immunostaining with an anti-TTR antibody confirmed deposition of TTR fibrils in glomeruli obtained from this patient; a control

Figure 1 TTR and HS S-domains colocalize in the kidney of a 38-year-old patient with ATTR amyloidosis (V30M mutation). **A:** Renal sections were stained with Congo red and confirm the presence of amyloid depositions under polarized light. **B:** Additional sections were stained with RB4CD12 antibody and anti-TTR antibody. The merged image indicates that RB4CD12 staining colocalizes with TTR deposits in the glomeruli. Postmortem kidney sections prepared from subjects without amyloidosis were also used (Control). **Boxed area** is shown at higher magnification below. The high-magnification image demonstrates segmentally variable deposition involving the mesangium and capillary wall. **C:** Renal sections from patients with ATTR amyloidosis who underwent liver transplantation (LT; ATTR number 5 through 8 + LT; **bottom row**) or did not undergo liver transplantation (ATTR number 1 through 4; **top row**) were stained with anti-TTR antibody (green) and RB4CD12 antibody (red). Scale bars: 50 μ m (**A**, **B**, **main images**, and **C**); 25 μ m (**B**, **high-magnification**).

section had no such deposition (**Figure 1A**). Expression of RB4CD12 epitopes was analyzed in sections from the same patient. Localized RB4CD12 epitopes (ie, highly sulfated domains of HS) were observed in glomeruli of this patient (**Figure 1B**). RB4CD12 signals completely overlapped with TTR signals (**Figure 1B**). The high-magnification image shows segmentally variable deposition involving the mesangium and capillary wall (**Figure 1B**). Among patients tested, five of the eight patients had amyloid deposits in the glomeruli, and four of the eight patients were positive for RB4CD12 staining (**Table 1**). Three of the five patients who did not receive liver transplantation were positive for both TTR deposits and HS S-domains, and one patient had TTR deposits but was HS S-domain negative (**Figure 1C**). The HS S-domain-negative tissue was stained with the 10E4 anti-HS antibody that requires *N*-sulfated glucosamine.⁵⁰ Several punctate TTR deposits colocalized with the 10E4 signal, whereas relatively large deposits were negative for 10E4 staining (**Supplemental Figure S1**), which suggests the existence of an alternative aggregation pathway in addition to those that involve sulfated GAGs. Two of the three patients who received liver transplantation were positive for both TTR deposits and HS S-domains (**Figure 1C**).

Heparin Accelerates Fibril Formation by TTR Fragments in an S-Domain-Dependent Manner

Many studies reported that heparin, which is a structural analog of HS S-domains, enhanced amyloid formation or protein aggregation by various amyloidogenic proteins.²³ We investigated whether HS S-domains would facilitate fibril formation by various TTR fragments. The aggregation propensity prediction tool AmylPred2⁵¹ was used with TTR. On the basis of the results, three TTR fragments (ie, the fragment with amino acid residues 12 to 35, where the heparin-binding motif is located⁴; the fragment with amino acid residues 12 to 35 carrying the V30M mutation; and the C-terminal fragment with amino acid residues 105 to 123, which were shown to be the major depositing fragments in patients with ATTR amyloidosis) were used (**Supplemental Figure S2**).⁵² Fibril formations of these three fragments, which were analyzed by using the amyloidophilic ThT dye, were enhanced within 30 to 50 minutes of incubation in the wells of heparin-BSA-coated plates (**Figure 2A**). It was then investigated whether the HS S-domain is critical for enhancing fibril formation by TTR fragments. To degrade the HS S-domains in these plates, immobilized heparin was

preincubated with concentrated culture medium of CHO cells that stably express HSulf-2. Elimination of HS S-domains was confirmed by using an enzyme-linked immunosorbent assay with RB4CD12 antibody (Figure 2B). Fibril formation by TTR fragments in these HS S-domain-eliminated plates was suppressed in 75 minutes from the beginning of the assay compared with that in plates that were treated with the conditioned medium of control CHO cells (the 12 to 35 fragment, 20%; the 12 to 35 mutated fragment, 5%; and the 105 to 123 fragment, 40%) (Figure 2C). Sulf-2 pretreatment completely abolished the fibril formation of TTR12-35/V30M (Figure 2C). These results clearly indicate that HS S-domains are critical for fibril formation accelerated by heparin. The ThT intensity began to decrease after an incubation time of approximately 4 hours (Figure 2C), possibly because of the absorption of fibrils to the wall of the well. However, ThT intensities were 1.5 (TTR 105 to 123) to 10 (TTR 12 to 35) times higher in

the mock-treated groups than in the HSulf-2-treated groups, which supports the importance of HS S-domains.

HSulf-2 Interferes with Interactions of Cells with TTR Fibrils and Cytotoxicity of TTR Fragments

A HSulf-2 stably expressing variant of CHO cells whose HS S-domains were reduced to approximately 20% to 50% of those of mock-transfected cells⁴⁰ was previously used, and it was found that the interactions of cells with fibrils of apoA-I fragments and cytotoxicity of these fibrils depended on HS S-domains at the cell surface.²⁰ Because fibrils of the TTR fragments that were used herein cannot be detected by immunocytochemical analysis or immunoblotting, fluorescently labeled TTR fibrils were used to analyze their interactions with cells. CHO cells and HSulf-2-expressing cells were then treated, after which the percentages of TTR fibril-positive cells were calculated. Formation of TTR

Figure 2 Heparin promotes fibril formation by TTR fragments in an HS S-domain-dependent manner. **A:** Fibril formation in bovine serum albumin (BSA)-coated or heparin-BSA-coated plates was determined by using the fluorescence-detected thioflavin T (ThT)-binding assay. **B:** To degrade HS S-domains within heparin chains, wells of heparin-BSA-coated plates were preincubated with HSulf-2-conditioned medium prepared from Chinese hamster ovary (CHO) cells that stably express HSulf-2. Elimination of HS S-domains was confirmed by using an enzyme-linked immunosorbent assay with the anti-S-domain antibody RB4CD12. **C:** Conditioned medium prepared from CHO cells that stably express a mock vector was used as a control. Fibril formation by TTR fragments markedly decreases after HS S-domains in immobilized heparin were removed. **Left column:** Fibril formation in heparin-BSA-coated plates was monitored for 75 minutes. **Right column:** Fibril formation in heparin-BSA-coated plates was monitored for 48 hours. Data are expressed as means $\pm$ SEM (no error bars appear when the error bars are smaller than the sizes of the symbols). $n = 5$ (A and C); $n = 3$ (B). *** $P < 0.001$ versus + mock. AU, arbitrary unit.

fibrils of these fragments was confirmed by using AFM (Figure 3A). The percentages of TTR fibril–positive cells were 50% to 75% and 20% to 25% in CHO and HSulf-2–expressing cells, respectively (Figure 3B). Contacts of these TTR fibrils with CHO cells significantly decreased as a result of the reduction in HS S-domains at the cell surface (Figure 3B). Also, interactions of TTR fibrils with cells were mediated by HS S-domains independently of the V30M mutation. Cytotoxicity of apoA-I fibrils (ie, induction of mitochondrial depolarization) depends on HS S-domains.²⁰ It was studied whether TTR fibrils caused the cytotoxicity. TTR fibrils caused mitochondrial depolarization in cells, as measured with the mitochondrial potential–sensitive tetramethylrhodamine, ethyl ester, dye (Figure 3C), which indicates that HS S-domains mediated interactions of cells with TTR fibrils and the cytotoxicity of these TTR fibrils regardless of the TTR mutation or the TTR fragment.

GPC5 Accumulates in the ATTR Amyloidosis Kidney and Increases in Mesangial Cells after TTR Fibril Treatment

A major cause of death in various systemic amyloidoses, including ATTR amyloidosis, is kidney dysfunction.³⁷ Okamoto et al⁴² identified *GPC5*, a member of the heparan sulfate proteoglycan family, as a susceptible gene for acquired nephrotic syndrome and showed that GPC5 mediated the harmful effects of excessive FGF2 on glomeruli.⁵³ As an

interesting result, colocalization of GPC5 and HS S-domains was observed in the glomeruli of a patient with ATTR amyloidosis (Figure 4A). No signals were observed when control tissues were stained with an isotype rabbit IgG or an isotype mouse IgG (Supplemental Figure S3). Because GPC5 in the kidney is expressed by mesangial cells and podocytes,⁴² the effect of TTR fibrils on expression of GPC5 was next studied in cultured mesangial cells and podocytes. The expression of GPC5 in mesangial cells, but not in podocytes, was enhanced by treatment with fibrils of C-terminal fragments of TTR, which often accumulated in patients' tissues or organs (Figure 4B).⁵² In addition, HS S-domains coimmunoprecipitated with GPC5 in TTR fibril-treated mesangial cells (Figure 4C), which suggests that GPC5 is a candidate core protein of HS S-domains in mesangial cells. Increased GPC5 induced glomerular accumulation of FGF2.⁵³ In agreement with that result, accumulation of FGF2 and its colocalization with GPC5 and TTR deposits was seen in glomeruli of a patient with ATTR amyloidosis (Figure 5 and Supplemental Figure S4).

Discussion

Since the identification of HS as a codeposited component of tissue amyloid in experimental AA amyloidosis,⁹ certain studies have suggested that HS affects the

Figure 3 Stable expression of HSulf-2 inhibits interactions of cells with TTR fibrils and cytotoxicity of fibrils of TTR fragments. **A:** Atomic force microscopy (AFM) images of TTR fibrils formed by the wild-type and V30M mutant TTR 12 to 35 fragments and the 105 to 123 fragments. TTR fibrils were obtained by incubating these TTR fragments (30 $\mu\text{mol/L}$) at 37°C for 7 days, after which the AFM analysis was performed. **B:** Nontransfectant Chinese hamster ovary (CHO) cells (CHO) and transfectants that stably expressed HSulf-2 (SULF2) were plated on poly-L-lysine–coated coverslips, treated with 1 $\mu\text{mol/L}$ TTR fibrils that were fluorescently labeled, and examined with a confocal microscope. Percentages of TTR fibril–positive CHO and SULF2 cells were determined. **C:** Nontransfected and HSulf-2–transfected CHO cells were seeded onto 24-well plates and treated with 1 $\mu\text{mol/L}$ TTR fibrils, after which the membrane potential of mitochondria was analyzed by using tetramethylrhodamine, ethyl ester, dye. The graphs show the percentages of cells with depolarized mitochondria. The control is the result for cells treated with the same amounts of phosphate-buffered saline as those used for cells treated with TTR fibrils. Data are expressed as means $\pm$ SEM (**B** and **C**). $n = 3$ independent experiments (**B** and **C**). * $P < 0.05$, ** $P < 0.01$ versus nontransfectants. Scale bars = 2 μm (**A**).

Figure 4 Accumulation of glypican-5 (GPC5) in the ATTR amyloidosis kidney and effects of TTR fibrils on GPC5 expression in kidney cells. **A:** Amyloid-positive sections were stained with an anti-GPC5 antibody (green) and the RB4CD12 antibody (red). GPC5 accumulates in the ATTR amyloidosis kidney and colocalizes with HS S-domains. Postmortem kidney sections prepared from subjects without amyloidosis were also used (Control). **B:** Immortalized human podocytes and mesangial cells were cultured and then treated with 1 μ M TTR fibrils for 24 hours, after which levels of GPC5 protein were analyzed by means of Western blot analysis. The graphs show quantification of GPC5. TTR fibril treatment enhances expression of GPC5 in mesangial cells but not in podocytes. **C:** HS S-domains in TTR fibril-treated cells immunoprecipitate together with the anti-GPC5 antibody in MES 13 cells. Cells that were treated with TTR fibrils were homogenized by sonication in radioimmunoprecipitation assay buffer containing a protease inhibitor cocktail followed by centrifugation at 1000 $\times$ g for 20 minutes at 4°C. Supernatants were harvested; GPC5–HS S-domain complexes were immunoprecipitated with an anti-GPC5 antibody; and HS S-domains in the immunoprecipitants were detected by Western blot analysis with the RB4CD12 antibody. Data are expressed as means $\pm$ SEM (**B**). $n = 3$ independent experiments (**B**). ** $P < 0.01$ versus nontreated cells. Scale bars = 50 μ m (**A**). IB, immunoblot; IP, immunoprecipitation; PBS, phosphate-buffered saline.

aggregation of various amyloidogenic proteins.²³ The ability of HS and/or heparin to promote protein aggregation depended on the degree of sulfation. However, the involvement of an S-domain, which is highly sulfated and a key element in the biological functions of HS, in systemic amyloidosis has never been addressed. Herein, we showed that HS S-domains colocalized with TTR amyloid deposits in tissues from patients with ATTR amyloidosis. The ability of heparin to promote aggregation of various TTR fragments was reduced by eliminating HS S-domains in polysaccharide chains, which suggests that heparin-mediated fibril formation of TTR fragments depended on HS S-domains. Given that HS or heparin serves as a scaffold by collecting monomers and promotes aggregation of a model peptide for amyloidogenic proteins,⁵⁴ our results strongly suggest that HS S-domains play a central role in collecting the monomers of the N-terminal fragment of TTR that have a heparin-binding motif.⁴ Aggregation of the C-terminal fragment of TTR was observed without heparin within 20 minutes and was accelerated by heparin. Thus, although the C-terminal fragment of TTR does not include a heparin-binding site,⁴ denatured small intermediates or seeds for aggregation may acquire a heparin-binding ability via conformational changes, and the subsequent aggregation process may depend on HS S-domains. Also, the C-terminal 49 to 127 fragments that are released by a proteolytic cleavage are highly amyloidogenic.⁵⁵ Elucidation of the molecular mechanism of TTR aggregation in the presence of heparin is a challenge for the future.

HS also mediates interactions of cells with protein aggregates. For example, HS is a primary receptor for infectious prion,^{56–58} and HS at the cell surface mediated A β cytotoxicity.¹⁹ HS, and especially its HS S-domains, mediates interactions of cells with apoA-I fibrils.²⁰ These results indicate a potential role of HS S-domains in interactions of cells with protein aggregates or uptake of protein aggregates. Also, in the present study, elimination of HS S-domains by HSulf-2 markedly decreased interactions of cells with TTR fibrils, which suggests that HS S-domains are critical for interactions of cells with TTR fibrils as well as for fibril formation. Although the C-terminal TTR fragment reportedly lacks heparin-binding ability,⁴ interactions of the C-terminal TTR fragment fibrils with cells and the subsequent cytotoxicity were reduced by HSulf-2, which suggests that fibrils of the C-terminal TTR fragment acquired heparin-binding ability by aggregating into amyloid fibrils. The G26R variant apoA-I forms fibrils in a heparin-independent manner,⁵⁹ and its interactions with cells and cytotoxicity depend on HS S-domains at the cell surface.²⁰ These lines of evidence suggest that binding molecules of amyloid fibrils before and after fibril formation may differ.

TTR exists physiologically as a tetramer with only a small amount of monomer,⁶⁰ and the initial step of TTR aggregation is dissociation of TTR tetramers into monomers.³³ With regard to serum AA, Noborn et al⁶¹ reported

Figure 5 Fibroblast growth factor 2 (FGF2) accumulates in the kidney of a 38-year-old patient with V30M ATTR amyloidosis. Renal sections were stained with an anti-FGF2 antibody (red) and an anti-glypican-5 (GPC5) antibody (green). GPC5 staining colocalizes with FGF2 staining in the glomeruli (Merge). Scale bars = 50 μ m.

that HS dissociated serum AA from high-density lipoprotein and thereby promoted serum AA aggregation. Thus, whether HS and heparin affect the stability of TTR tetramers is also of interest. Several tissues and organs, including the kidney, are enriched with HS and HS S-domains regardless of the presence of amyloid deposits, and Sulf s are at least partly involved in the expression of HS S-domains.⁶² Because these results suggest that HS S-domains accelerated TTR aggregation and mediated the cytotoxicity of TTR fragments, analysis of the disaccharide compositions and Sulf levels in various tissues and organs with or without amyloid deposits will broaden the current understanding of the role of HS S-domains in amyloidosis.

Although the principal manifestation of most ATTR amyloidosis is peripheral neuropathy, the kidney is also a main organ with amyloid deposition in ATTR amyloidosis.⁶³ The clinical manifestations range from proteinuria to end-stage renal failure, although proteinuria is the most frequent manifestation.^{64,65} Proteinuria has been well established as resulting from defects in the glomerular filtration barrier.⁶⁶ Although the mechanisms of organ dysfunction in amyloidosis include physical disruption of tissues that is caused by accumulation of amyloid fibrils in the extracellular spaces and direct cytotoxicity of the amyloid fibrils or oligomers,³⁶ some common structural defects may occur in diabetes and amyloidosis-related renal dysfunction.⁶⁷ Okamoto et al⁴² identified *GPC5* as a novel gene that is involved in the susceptibility to acquired nephrotic syndrome. They also showed that podocyte-specific knockdown of *GPC5* prevented podocyte injury in mouse models of nephrosis. Herein, we showed that GPC5 accumulated in glomeruli of a patient with ATTR amyloidosis, which strongly suggests that GPC5 may be involved in renal dysfunction in this disorder. GPC5 is an HS-carrying proteoglycan and one of the six members of the glycosylphosphatidylinositol-anchored glypican family.⁶⁸ Because GPC5 can be cleaved,⁶⁹ membrane-anchored GPC5 may be released and may accumulate in glomerular

TTR deposits. One of the core proteins of HS S-domains that codeposit with TTR amyloid may be GPC5. The kidney and glomeruli express other core proteins of proteoglycans, including those of the extracellular matrix. Additional studies to identify the other core proteins are absolutely necessary.

FGF2 is a highly conserved cationic protein and is released from cytoplasmic storage sites in response to cell injury. In the kidney, FGF2 is reportedly synthesized by glomerular mesangial cells⁷⁰ and podocytes,⁷¹ and it stimulates proliferation of these cells *in vitro*. Optimal activities of FGF2 require glypicans,⁷² including GPC5.⁷³ Although FGF2 stimulated proliferation of glomerular mesangial cells, endothelial cells, and podocytes,^{71,74,75} an excess amount of FGF2 was harmful to glomeruli and induced proteinuria.^{76,77} Podocyte-specific knockdown of *GPC5* has also reduced FGF2-induced podocyte injury and proteinuria by inhibiting FGF2 binding to cells.⁴² Thus, the accumulation of both GPC5 and FGF2 in glomeruli of patients with ATTR amyloidosis, as observed herein, indicates that hyperactivation of FGF2 signaling via GPC5 may have a role in amyloid nephropathy in ATTR amyloidosis. The mechanism by which accumulation of GPC5 and FGF2 was induced is currently unknown. GPC5 may have accumulated as a core protein of the HS S-domains that also occurred in glomeruli with amyloid. FGF2 was released after cell damage,⁷⁸ so podocytes or mesangial cells may also release FGF2 in response to amyloid fibril-induced cell damage. Although *FGF2* gene transfer reportedly restored hippocampal functions in an AD mouse model,⁷⁹ the roles of FGF2 signaling in other systemic and localized amyloidosis remain to be elucidated. Additional studies to clarify these mechanisms are essential before considering GPC5 and FGF2 as therapeutic targets in amyloid nephropathy in ATTR amyloidosis. Inasmuch as the kidney is a common target in several systemic amyloidosis, addressing the involvement of GPC5 and FGF2 in amyloid nephropathy that occurs in other amyloidosis would also be of interest.

Sulf-2 is an enzyme that remodels HS extracellularly by removing 6-O-sulfate groups on glucosamine residues in the HS S-domains within heparin and HS.^{40,80} A previous knockout study suggested that Sulf-2 contributed to the occurrence and maintenance of specific sulfation patterns of HS in various organs, such as the kidney,⁶² which is one of the major sites and targets for amyloid deposition and amyloid-related damage in several systemic amyloidosis, including ATTR amyloidosis. Transfectant CHO cells that stably express HSulf-1 or HSulf-2 interact less with Iowa mutation of apoA-I fibrils compared with nontransfectant CHO cells.²⁰ On the basis of the finding that HS S-domains that were degraded by Sulf-2 accumulated in senile plaques in AD patients,²² we proposed that enzymatic remodeling of HS by Sulf-2 may modulate the pathogenesis or pathology of localized and systemic amyloidosis, such as AD and Iowa mutation of apoA-I amyloidosis.⁴³ With regard to FGF, FGF signaling requires heparan sulfate proteoglycans to form stable ligand/receptor complexes,⁸¹ because the

6-*O*-sulfate group of heparin and HS plays a critical role in FGF-FGF receptor binding and dimerization of the FGF receptor.^{82,83} Thus, our study supports the idea that enzymatic remodeling of HS may affect not only deposition of amyloid fibrils but also clinical manifestations in amyloidoses via modulating various signaling pathways, including FGF signaling. Our results also lead us to propose that the activity or protein levels of endogenous Sulf-2 may be involved in the pathogenesis, progression, and clinical manifestation of amyloidoses. The correlation between Sulf-2 and GPC5 is currently not clear. The finding showing accumulation of HS S-domains in kidneys of ATTR patients suggests that Sulf-2 activity may be affected in ATTR amyloidosis. Because reports have shown that Sulf-2 negatively regulates and GPC5 positively regulates FGF2 signaling,^{41,73} additional studies are required.

On the basis of these results, we therefore propose that HS S-domains, which can be enzymatically remodeled by Sulf-2, act as a scaffold for formation of TTR fibrils and mediate interactions of the fibrils with cells. Our idea of modulating amyloid deposition and clinical symptoms by enzymatic remodeling is not limited to ATTR amyloidosis but can be applied to various systemic and localized amyloidoses. The glomerular accumulation of GPC5 and FGF2 suggested hyperactivation of FGF2 signaling, which is an attractive candidate as a therapeutic target in renal dysfunction in systemic amyloidoses. Additional studies to confirm these possibilities are needed. Amyloid deposits were observed in the mesangium and capillary walls, but the mechanism by which TTR or TTR fibrils pass through the endothelial barrier and reach the mesangium is currently unknown. With regard to A β , Marco and Skaper⁸⁴ suggested that A β has a detrimental effect on the endothelial barrier at the brain-blood barrier. Effects of amyloid fibrils on endothelial cells are also yet to be clarified. Finally, the contents of HS S-domains vary among tissues, organs, and various types of cells. Determining the HS S-domain contents in various tissues, organs, and cells and using tissue-derived HS may provide clues to understanding the tissue specificity of deposition and damage by amyloid fibrils.

Acknowledgments

We thank Tomoki Yoshioka for technical help, the Support Center for Advanced Medical Sciences (Institute of Biomedical Sciences, Tokushima University), and Dr. Toin H. van Kuppevelt (Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands) for providing RB4CD12 antibody.

H.K., K.K., T.M., T.K., and K.O. performed the experiments; M.M. prepared the C-terminal fragments or transthyretin and interpreted the data; S.-C.H. prepared the heparin–bovine serum albumin conjugates and interpreted the data; T.O. and H.S. performed the atomic force microscopy analysis; T.Y. and Y.A. performed the

immunohistochemical analysis; K.U. interpreted the data and supervised the entire project; K.N. designed the study, interpreted the data, wrote the article, and takes full responsibility for the article; all authors reviewed the results and approved the final version of the article.

Supplemental Data

Supplemental material for this article can be found at <https://doi.org/10.1016/j.ajpath.2018.09.015>.

References

1. Lyon M, Gallagher JT: Bio-specific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion. *Matrix Biol* 1998, 17:485–493
2. Gallagher JT: Heparan sulfate: growth control with a restricted sequence menu. *J Clin Invest* 2001, 108:357–361
3. Esko JD, Selleck SB: Order out of chaos: assembly of ligand binding sites in heparan sulfate. *Annu Rev Biochem* 2002, 71:435–471
4. Noborn F, O'Callaghan P, Hermansson E, Zhang X, Ancsin JB, Damas AM, Dacklin I, Presto J, Johansson J, Saraiva MJ, Lundgren E, Kisilevsky R, Westermark P, Li JP: Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. *Proc Natl Acad Sci U S A* 2011, 108:5584–5589
5. Snow AD, Mar H, Nochlin D, Kimata K, Kato M, Suzuki S, Hassell J, Wight TN: The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. *Am J Pathol* 1988, 133:456–463
6. Snow AD, Mar H, Nochlin D, Sekiguchi RT, Kimata K, Koike Y, Wight TN: Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. *Am J Pathol* 1990, 137:1253–1270
7. van Horssen J, Kleinnijenhuis J, Maass CN, Rensink AA, Otte-Holler I, David G, van den Heuvel LP, Wesseling P, de Waal RM, Verbeek MM: Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. *Neurobiol Aging* 2002, 23:537–545
8. Young ID, Willmer JP, Kisilevsky R: The ultrastructural localization of sulfated proteoglycans is identical in the amyloids of Alzheimer's disease and AA, AL, senile cardiac and medullary carcinoma-associated amyloidosis. *Acta Neuropathol* 1989, 78:202–209
9. Snow AD, Kisilevsky R: Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis: a histochemical study. *Lab Invest* 1985, 53:37–44
10. Bourgault S, Solomon JP, Reixach N, Kelly JW: Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. *Biochemistry* 2011, 50:1001–1015
11. Castillo GM, Lukito W, Wight TN, Snow AD: The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. *J Neurochem* 1999, 72:1681–1687
12. McLaurin J, Franklin T, Zhang X, Deng J, Fraser PE: Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. *Eur J Biochem* 1999, 266:1101–1110
13. Bravo R, Arimon M, Valle-Delgado JJ, Garcia R, Durany N, Castel S, Cruz M, Ventura S, Fernandez-Busquets X: Sulfated polysaccharides promote the assembly of amyloid beta(1-42) peptide into stable fibrils of reduced cytotoxicity. *J Biol Chem* 2008, 283:32471–32483
14. Blancas-Mejia LM, Hammernik J, Marin-Argany M, Ramirez-Alvarado M: Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans. *J Biol Chem* 2015, 290:4953–4965

15. Ancsin JB, Kisilevsky R: The heparin/heparan sulfate-binding site on apo-serum amyloid A: implications for the therapeutic intervention of amyloidosis. *J Biol Chem* 1999, 274:7172–7181
16. Takase H, Tanaka M, Yamamoto A, Watanabe S, Takahashi S, Nadanaka S, Kitagawa H, Yamada T, Mukai T: Structural requirements of glycosaminoglycans for facilitating amyloid fibril formation of human serum amyloid A. *Amyloid* 2016, 23:67–75
17. Aguilera JJ, Zhang F, Beaudet JM, Linhardt RJ, Colon W: Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid A. *Biochimie* 2014, 104:70–80
18. Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, Kotzbauer PT, Miller TM, Papy-Garcia D, Diamond MI: Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. *Proc Natl Acad Sci U S A* 2013, 110: E3138–E3147
19. Sandwall E, O'Callaghan P, Zhang X, Lindahl U, Lannfelt L, Li JP: Heparan sulfate mediates amyloid-beta internalization and cytotoxicity. *Glycobiology* 2010, 20:533–541
20. Kuwabara K, Nishitsuji K, Uchimura K, Hung SC, Mizuguchi M, Nakajima H, Mikawa S, Kobayashi N, Saito H, Sakashita N: Cellular interaction and cytotoxicity of the Iowa mutation of apolipoprotein A-I (ApoA-IIowa) amyloid mediated by sulfate moieties of heparan sulfate. *J Biol Chem* 2015, 290:24210–24221
21. Bruinsma IB, te Riet L, Gevers T, ten Dam GB, van Kuppevelt TH, David G, Kusters B, de Waal RM, Verbeek MM: Sulfation of heparan sulfate associated with amyloid-beta plaques in patients with Alzheimer's disease. *Acta Neuropathol* 2010, 119:211–220
22. Hosono-Fukao T, Ohtake-Niimi S, Hoshino H, Britschgi M, Akatsu H, Hossain MM, Nishitsuji K, van Kuppevelt TH, Kimata K, Michikawa M, Wyss-Coray T, Uchimura K: Heparan sulfate subdomains that are degraded by Sulf accumulate in cerebral amyloid β plaques of Alzheimer's disease: evidence from mouse models and patients. *Am J Pathol* 2012, 180:2056–2067
23. Nishitsuji K, Uchimura K: Sulfated glycosaminoglycans in protein aggregation diseases. *Glycoconj J* 2017, 34:453–466
24. Nishitsuji K: Heparan sulfate S-domains and extracellular sulfatases (Sulfs): their possible roles in protein aggregation diseases. *Glycoconj J* 2018, [Epub ahead of print] doi:10.1007/s10719-018-9833-8
25. Eanes ED, Glenner GG: X-ray diffraction studies on amyloid filaments. *J Histochem Cytochem* 1968, 16:673–677
26. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westernmark P: Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. *Amyloid* 2014, 21:221–224
27. Connors LH, Lim A, Prokava T, Roskens VA, Costello CE: Tabulation of human transthyretin (TTR) variants, 2003. *Amyloid* 2003, 10:160–184
28. Raz A, Shiratori T, Goodman DS: Studies on the protein-protein and protein-ligand interactions involved in retinol transport in plasma. *J Biol Chem* 1970, 245:1903–1912
29. Saraiva MJ, Birken S, Costa PP, Goodman DS: Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type: definition of molecular abnormality in transthyretin (prealbumin). *J Clin Invest* 1984, 74:104–119
30. Buxbaum J, Koziol J, Connors LH: Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. *Amyloid* 2008, 15:255–261
31. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Plante-Bordeneuve V, Rapezzi C, Said G, Salvi F: Guideline of transthyretin-related hereditary amyloidosis for clinicians. *Orphanet J Rare Dis* 2013, 8:31
32. Teng MH, Yin JY, Vidal R, Ghiso J, Kumar A, Rabenou R, Shah A, Jacobson DR, Tagoe C, Gallo G, Buxbaum J: Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. *Lab Invest* 2001, 81:385–396
33. Buxbaum JN, Reixach N: Transthyretin: the servant of many masters. *Cell Mol Life Sci* 2009, 66:3095–3101
34. Theis JD, Dasari S, Vrana JA, Kurtin PJ, Dogan A: Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis. *J Mass Spectrom* 2013, 48:1067–1077
35. Kisilevsky R, Ancsin JB, Szarek WA, Petanceska S: Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. *Amyloid* 2007, 14:21–32
36. Dember LM: Amyloidosis-associated kidney disease. *J Am Soc Nephrol* 2006, 17:3458–3471
37. Lobato L, Rocha A: Transthyretin amyloidosis and the kidney. *Clin J Am Soc Nephrol* 2012, 7:1337–1346
38. Farquhar M: The glomerular basement membrane: a selective macromolecular filter. Edited by Hay ED. In *Cell Biology of the Extracellular Matrix*. ed 2. New York: Plenum Press, 1991. pp. 365–412
39. Dennissen MA, Jenniskens GJ, Pieffers M, Versteeg EM, Petitou M, Veerkamp JH, van Kuppevelt TH: Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies. *J Biol Chem* 2002, 277:10982–10986
40. Hossain MM, Hosono-Fukao T, Tang R, Sugaya N, van Kuppevelt TH, Jenniskens GJ, Kimata K, Rosen SD, Uchimura K: Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88. *Glycobiology* 2010, 20:175–186
41. Rosen SD, Lemjabbar-Alaoui H: Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate. *Expert Opin Ther Targets* 2010, 14:935–949
42. Okamoto K, Tokunaga K, Doi K, Fujita T, Suzuki H, Katoh T, Watanabe T, Nishida N, Mabuchi A, Takahashi A, Kubo M, Maeda S, Nakamura Y, Noiri E: Common variation in GPC5 is associated with acquired nephrotic syndrome. *Nat Genet* 2011, 43:459–463
43. Nishitsuji K, Saito H, Uchimura K: Enzymatic remodeling of heparan sulfate: a therapeutic strategy for systemic and localized amyloidoses? *Neural Regen Res* 2016, 11:408–409
44. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P: A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. *J Am Soc Nephrol* 2002, 13:630–638
45. Najjam S, Gibbs RV, Gordon MY, Rider CC: Characterization of human recombinant interleukin 2 binding to heparin and heparan sulfate using an ELISA approach. *Cytokine* 1997, 9:1013–1022
46. Naiki H, Higuchi K, Hosokawa M, Takeda T: Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. *Anal Biochem* 1989, 177:244–249
47. Nakajima H, Nishitsuji K, Kawashima H, Kuwabara K, Mikawa S, Uchimura K, Akaji K, Kashiwada Y, Kobayashi N, Saito H, Sakashita N: The polyphenol (-)-epigallocatechin-3-gallate prevents apoA-IIowa amyloidosis in vitro and protects human embryonic kidney 293 cells against amyloid cytotoxicity. *Amyloid* 2016, 23:17–25
48. Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, Gallagher J, Werb Z, Rosen SD: HSulf-2, an extracellular endoglucosaminase-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. *BMC Biochem* 2006, 7:2
49. Puchtler H, Sweat F: Congo red as a stain for fluorescence microscopy of amyloid. *J Histochem Cytochem* 1965, 13:693–694
50. David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H: Developmental changes in heparan sulfate expression: in situ detection with mAbs. *J Cell Biol* 1992, 119:961–975
51. Tsois AC, Papandreou NC, Iconomidou VA, Hamodrakas SJ: A consensus method for the prediction of "aggregation-prone" peptides in globular proteins. *PLoS One* 2013, 8:e54175
52. Bergstrom J, Gustavsson A, Hellman U, Sletten K, Murphy CL, Weiss DT, Solomon A, Olofsson BO, Westernmark P: Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. *J Pathol* 2005, 206: 224–232
53. Okamoto K, Honda K, Doi K, Ishizu T, Katagiri D, Wada T, Tomita K, Ohtake T, Kaneko T, Kobayashi S, Nangaku M, Tokunaga K, Noiri E: Glypican-5 increases susceptibility to nephrotic damage in diabetic kidney. *Am J Pathol* 2015, 185:1889–1898

54. Motamedi-Shad N, Monsellier E, Chiti F: Amyloid formation by the model protein muscle acylphosphatase is accelerated by heparin and heparan sulphate through a scaffolding-based mechanism. *J Biochem* 2009, 146:805–814
55. Marcoux J, Mangione PP, Porcari R, Degiacomi MT, Verona G, Taylor GW, Giorgetti S, Raimondi S, Sanglier-Cianferani S, Benesch JL, Cecconi C, Naqvi MM, Gillmore JD, Hawkins PN, Stoppini M, Robinson CV, Pepys MB, Bellotti V: A novel mechanoenzymatic cleavage mechanism underlies transthyretin amyloidogenesis. *EMBO Mol Med* 2015, 7:1337–1349
56. Horonchik L, Tzaban S, Ben-Zaken O, Yedidia Y, Rouvinski A, Papy-Garcia D, Barritault D, Vlodavsky I, Taraboulos A: Heparan sulfate is a cellular receptor for purified infectious prions. *J Biol Chem* 2005, 280:17062–17067
57. Hijazi N, Kariv-Inbal Z, Gasset M, Gabizon R: PrPSc incorporation to cells requires endogenous glycosaminoglycan expression. *J Biol Chem* 2005, 280:17057–17061
58. Shyng SL, Lehmann S, Moulder KL, Harris DA: Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. *J Biol Chem* 1995, 270:30221–30229
59. Mikawa S, Mizuguchi C, Nishitsuji K, Baba T, Shigenaga A, Shimanouchi T, Sakashita N, Otaka A, Akaji K, Saito H: Heparin promotes fibril formation by the N-terminal fragment of amyloidogenic apolipoprotein A-I. *FEBS Lett* 2016, 590:3492–3500
60. Sekijima Y, Tokuda T, Kametani F, Tanaka K, Maruyama K, Ikeda S: Serum transthyretin monomer in patients with familial amyloid polyneuropathy. *Amyloid* 2001, 8:257–262
61. Noborn F, Ancsin JB, Ubhayasekera W, Kisilevsky R, Li JP: Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein, promoting SAA aggregation. *J Biol Chem* 2012, 287:25669–25677
62. Nagamine S, Tamba M, Ishimine H, Araki K, Shiomi K, Okada T, Ohto T, Kunita S, Takahashi S, Wismans RG, van Kuppevelt TH, Masu M, Keino-Masu K: Organ-specific sulfation patterns of heparan sulfate generated by extracellular sulfatases Sulf1 and Sulf2 in mice. *J Biol Chem* 2012, 287:9579–9590
63. Jennette J, Heptinstall RH: *Heptinstall's Pathology of the Kidney*. ed 6. Philadelphia, PA, Lippincott Williams & Wilkins, 2007
64. Lobato L, Beirao I, Silva M, Bravo F, Silvestre F, Guimaraes S, Sousa A, Noel LH, Sequeiros J: Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy. *Nephrol Dial Transplant* 2003, 18:532–538
65. Lobato L, Beirao I, Silva M, Fonseca I, Queiros J, Rocha G, Sarmiento AM, Sousa A, Sequeiros J: End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. *Amyloid* 2004, 11:27–37
66. Haraldsson B, Nystrom J, Deen WM: Properties of the glomerular barrier and mechanisms of proteinuria. *Physiol Rev* 2008, 88:451–487
67. Vaamonde CPG, Pardo V: Dysproteinemias: multiple myeloma, amyloidosis and related disorders. Edited by Schrier R, Gottschalk C. In *Diseases of the Kidney*. ed 5. Boston, MA: Little, Brown, 1992. pp. 2189–2237
68. Filmus J, Selleck SB: Glypicans: proteoglycans with a surprise. *J Clin Invest* 2001, 108:497–501
69. Fujihara Y, Ikawa M: GPI-AP release in cellular, developmental, and reproductive biology. *J Lipid Res* 2016, 57:538–545
70. Floege J, Eng E, Lindner V, Alpers CE, Young BA, Reidy MA, Johnson RJ: Rat glomerular mesangial cells synthesize basic fibroblast growth factor: release, upregulated synthesis, and mitogenicity in mesangial proliferative glomerulonephritis. *J Clin Invest* 1992, 90:2362–2369
71. Takeuchi A, Yoshizawa N, Yamamoto M, Sawasaki Y, Oda T, Senoo A, Niwa H, Fuse Y: Basic fibroblast growth factor promotes proliferation of rat glomerular visceral epithelial cells in vitro. *Am J Pathol* 1992, 141:107–116
72. Mertens G, Van der Schueren B, van den Berghe H, David G: Heparan sulfate expression in polarized epithelial cells: the apical sorting of glypican (GPI-anchored proteoglycan) is inversely related to its heparan sulfate content. *J Cell Biol* 1996, 132:487–497
73. Williamson D, Selfe J, Gordon T, Lu YJ, Pritchard-Jones K, Murai K, Jones P, Workman P, Shipley J: Role for amplification and expression of glypican-5 in rhabdomyosarcoma. *Cancer Res* 2007, 67:57–65
74. Issandou M, Darbon JM: Basic fibroblast growth factor stimulates glomerular mesangial cell proliferation through a protein kinase C-independent pathway. *Growth Factors* 1991, 5:255–264
75. Ballermann BJ: Regulation of bovine glomerular endothelial cell growth in vitro. *Am J Physiol* 1989, 256:C182–C189
76. Kriz W, Hähnel B, Rösener S, Elger M: Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis. *Kidney Int* 1995, 48:1435–1450
77. Floege J, Kriz W, Schulze M, Susani M, Kerjaschki D, Mooney A, Couser WG, Koch KM: Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. *J Clin Invest* 1995, 96:2809–2819
78. Floege J, Eng E, Young BA, Alpers CE, Barrett TB, Bowen-Pope DF, Johnson RJ: Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. *J Clin Invest* 1993, 92:2952–2962
79. Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T: FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders. *Proc Natl Acad Sci U S A* 2011, 108:E1339–E1348
80. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD: Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. *J Biol Chem* 2002, 277:49175–49185
81. Ornitz DM, Marie PJ: FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. *Genes Dev* 2002, 16:1446–1465
82. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC: Activating and inhibitory heparin sequences for FGF-2 (basic FGF): distinct requirements for FGF-1, FGF-2, and FGF-4. *J Biol Chem* 1993, 268:23906–23914
83. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M: Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. *Mol Cell* 2000, 6:743–750
84. Marco S, Skaper SD: Amyloid beta-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. *Neurosci Lett* 2006, 401:219–224